- Valbiotis announces positive results in the bioavailability and mode of action TOTUM•854 clinical study, against high blood pressure. Voir le communiqué de presse
- Provision of preparatory documents for the Extraordinary General Assembly (IN FRENCH). Voir le communiqué de presse
- Valbiotis announces its roadmap for 2023: a pivotal year in the execution of its clinical, industrial and commercial strategy. Voir le communiqué de presse
- Valbiotis announces the signature of a research partnership in intestinal microbiota with the MEDIS Unit from the Clermont Auvergne University. Voir le communiqué de presse
- Consolidated sales for the third quarter of 2022: €54.8 million (IN FRENCH). Voir le communiqué de presse
- Valbiotis will present significant preclinical results for its active substance TOTUM•448 against fatty liver diseases (NAFL and NASH), at the annual meeting of the American Association for the Study of Liver Diseases (AASLD). Voir le communiqué de presse
